Imatinib Activates Pathological Hypertrophy by Altering Myocyte Calcium Regulation

BACKGROUND: Imatinib mesylate is a selective tyrosine‐kinase inhibitor used in the treatment of multiple cancers, most notably chronic myelogenous leukemia. There is evidence that imatinib can induce cardiotoxicity in cancer patients. Our hypothesis is that imatinib alters calcium regulatory mechani...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Barr, Larry A., Makarewich, Catherine A., Berretta, Remus M., Gao, Hui, Troupes, Constantine D., Woitek, Felix, Recchia, Fabio, Kubo, Hajime, Force, Thomas, Houser, Steven R.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2014
Assuntos:
Original Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4213285/
https://ncbi.nlm.nih.gov/pubmed/24931551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12173
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados